Share

January 08, 2013; 80 (2) Article

Can MRI screen for CSF biomarkers in neurodegenerative disease?

Corey T. McMillan, Brian Avants, David J. Irwin, Jon B. Toledo, David A. Wolk, Vivianna M. Van Deerlin, Leslie M. Shaw, John Q. Trojanoswki, Murray Grossman
First published December 26, 2012, DOI: https://doi.org/10.1212/WNL.0b013e31827b9147
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
627

Share

Article Information

vol. 80 no. 2 132-138
DOI: 
https://doi.org/10.1212/WNL.0b013e31827b9147
PubMed: 
23269595
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received May 17, 2012
  • Accepted August 14, 2012
  • First Published December 26, 2012.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Corey T. McMillan, PhD,
    2. Brian Avants, PhD,
    3. David J. Irwin, MD,
    4. Jon B. Toledo, MD,
    5. David A. Wolk, MD,
    6. Vivianna M. Van Deerlin, MD, PhD,
    7. Leslie M. Shaw, PhD,
    8. John Q. Trojanoswki, MD, PhD and
    9. Murray Grossman, MD, EdD
  1. Corey T. McMillan, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH NRSA (F32): HD040604, NIH Loan Repayment Program

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Brian Avants, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. David J. Irwin, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH/NIA T32-AG000255 Research Fellow/Trainee 2010, NIH/NIA P30 AG010124-20 Research Fellow/Trainee 2010.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Jon B. Toledo, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Jon B Toledós work is supported by the Martín Escudero Foundation.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. David A. Wolk, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. GE Healthcare, Inc

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. GE Healthcare, Inc. 2. Pfizer

    Research Support, Government Entities:

    1. 1. NIH, AG028018, PI, 09/30/06-07/31/11 2. NIH, AG037376, Co-I, 05/01/09 - 04/30/14, 3. NIH, MH086492, Co-I, 05/14/10 - 3/31/14, 4. NIH, AG010124, Co-I, 08/01/2006 - 06/30/2011, 5. PA Department of Health, 600594-6, Co-I, 10/01/2008 - 05/31/2009

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Vivianna M. Van Deerlin, MD, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Member, Editorial Board, “Molecular Diagnosis & Therapy” Guest editor, special cluster issue on neurodegenerative disease genetics, Acta Neuropathologica

    Patents:

    1. NONE

    Publishing Royalties:

    1. Molecular Pathology in Clinical Practice. Leonard DGB, Bagg A, Caliendo AM, Kaul KL, Van Deerlin VM (eds.). Springer, 2007 Notes: VM Van Deerlin, Section Editor, Identity Testing Section (pages 491-537). Royalties received

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH NS053488, NIH AG010124, NIH AG017586

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Leslie M. Shaw, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Speaker travel expenses, honorarium, Pfizer, 2009

    Editorial Boards:

    1. Editorial board member, Therapeutic Drug Monitoring, 1990-present

    Patents:

    1. O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders. This invention has been licensed by Penn to Novartis and Dr Shaw benefited financially from the license

    Publishing Royalties:

    1. Editor, Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring, Wolters Kluwer/Lippincott Williams & Wilkins, 2005-present

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Janssen AI R&D; Saladax Biomedical, Inc

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Research support from: NIH grant AG024904, Co-PI Biomarker Core Laboratory, 2004-2010, Alzheimer's disease Neuroimaging Initiative; NIH 1RC 2AG-036535 (ARRA), PI Biomarker Core Laboratory, 2010-2011; PI Biomarker Core Laboratory NIH Grant AG-024904-07 Alzheimer's Disease Neuroimaging 2; co-PI Parkinson's Progression Marker Initiative, sponsored by MJ Fox Foundation for Parkinson's Disease Research

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. member of board of directors, Saladax Biomedical, 2005-present

    License Fee Payments, Technology or Inventions:

    1. O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders. This invention has been licensed by Penn to Novartis and Dr Shaw benefited financially from the license

    Royalty Payments, Technology or Inventions:

    1. O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders. This invention has been licensed by Penn to Novartis and Dr Shaw benefited financially from the license

    Stock/Stock Options, Research Sponsor:

    1. stock options, Saladax Biomedical, 2005-present

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. John Q. Trojanoswki, MD, PhD and
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Dr. Trojanowski may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is co-Inventor and he received revenue from the sale of Avid to Eli Lily as co-inventor on imaging related patents submitted by the University of Pennsylvania while he receives research support from the NIH, Bristol Myer Squib, AstraZenica and several non-profits.

    Editorial Boards:

    1. Alzheimer's & Dementia, Associate Editor

    Patents:

    1. holds 14 patents that may accrue revenue: US Patent 5,281,521, issued 25 Jan 1994: Modified Avidin-Biotin Technique; US Patent 5,580,898, issued 3 Dec 1996: Method of Stabilizing Microtubules to Treat Alzheimer's Disease; US Patent 5,601,985, issued 11 Feb 1997: Method of Detecting Abnormally Phosphorylated Tau; US Patent 5,733,734, issued 31 Mar 1998: Method of Screening for Alzheimer's Disease or Disease Associated with the Accumulation of Paired Helical Filaments; US Patent 5,792,900, issued 11 Aug 1998: Compositions and Methods for Producing and Using Homogeneous Neuronal Cell Transplants; US Patent 5,849,988, issued 15 Dec 1998: Rat Comprising Straight Filaments in Its Brain; US Patent 6,214,334, issued 10 Apr 2001: Compositions And Methods for Producing and Using Homogeneous Neuronal Cell Transplants to Treat Neurodegenerative Disorders and Brain and Spinal Cord Injuries; US Patent 6,358,681, issued 19 Mar 2002: Diagnostic Methods for Alzheimer's Disease by Detection of Multiple MRNAs; US Patent 6,727,075, issued 27 Mar 2004: Methods and Compositions for Determining Lipid Peroxidation Levels in Oxidant Stress Syndromes and Diseases; US Patent 7,011,827, issued 14 Mar 2006: Compositions and Methods for Producing and Using Homogenous Neuronal Cell Transplants; Penn 0652, K1828, filed 5 Aug 1998: Method of Identifying, Diagnosing and Treating Alpha-synuclein Positive Neurodegenerative Disorders; Penn L1986, Filed 13 Nov 1998: Mutation-specific Functional Impairments in Distinct Tau Isoforms of Hereditary Frontotemporal Dementia and Parkinsonism Linked to Chromosome- 17: Genotype Predicts Phenotype; Penn R3868 (UPN-4439), filed 28 Feb 2005: Microtubule Stabilizing Therapies for Neurodegenerative Disorders; and Penn S-4018, DB&R 46406-217282, filed 22 Nov 2005: Treatment of Alzheimer's and Related Diseases with an Antibody

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. receives research support from the NIH (NIA P01 AG 09215-20 [PI], NIA P30 AG 10124-18 [PI], NIA PO1 AG 17586-10 [Project 4 Leader], NIA 1PO1 AG-19724-07 [Core C Leader], NIA 1 U01 AG 024904-05 [Co-PI Biomarker Core Laboratory], NINDS P50 NS053488-02 [PI], NIA UO1 AG029213-01 [Co-I]; RC2NS069368 [PI], RC1AG035427 [PI], and NIA P30AG036468 [PI])

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Marian S. Ware Alzheimer Program, Benaroya

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Murray Grossman, MD, EdD
    10. Scientific Advisory Boards:

    1. Allon Pharmaceutical; TauRx; Bristol Myers Squibb

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Editorial Advisory Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Forest, consultant, 2010; Allon, 2011

    Research Support, Government Entities:

    1. Research support from NIH: AG17586, AG15116, NS44266, NS53488, AG32953

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (C.T.M., D.J.I., D.A.W., M.G.), Center for Neurodegenerative Disease Research (D.J.I., J.B.T., V.M.V.D., L.M.S., J.Q.T.), Department of Radiology (B.A.), Penn Memory Center (D.A.W.), and Department of Pathology & Laboratory Medicine (V.M.V.D., L.M.S., J.Q.T.), University of Pennsylvania, Philadelphia.
  1. Correspondence to Dr. McMillan: mcmillac{at}mail.med.upenn.edu

Article usage

Article usage: December 2012 to October 2023

AbstractFullPdfSource
Dec 20121087279Highwire
Jan 2013299597203Highwire
Feb 20135512235Highwire
Mar 20135461626Highwire
Apr 2013366813Highwire
May 20132781111Highwire
Jun 2013180911Highwire
Jul 201312904Highwire
Aug 2013103510Highwire
Sep 201313946Highwire
Oct 201312376Highwire
Nov 201312235Highwire
Dec 201310013Highwire
Jan 201413342Highwire
Jan 20140205pmc
Feb 201410301Highwire
Mar 201412311Highwire
Apr 20149801Highwire
May 20148733Highwire
Jun 20148200Highwire
Jul 20146001Highwire
Aug 20144601Highwire
Sep 20146402Highwire
Oct 20147213Highwire
Nov 20148001Highwire
Dec 20147400Highwire
Jan 20158512Highwire
Jan 2015094pmc
Feb 20155201Highwire
Feb 2015052pmc
Mar 20158301Highwire
Mar 2015085pmc
Apr 20154600Highwire
Apr 20150116pmc
May 20153710Highwire
May 2015031pmc
Jun 20154300Highwire
Jun 2015045pmc
Jul 20158700Highwire
Jul 2015074pmc
Aug 20157521Highwire
Aug 2015076pmc
Sep 20156511Highwire
Sep 2015096pmc
Oct 20153810Highwire
Oct 2015074pmc
Nov 20153711Highwire
Nov 20150107pmc
Dec 20153000Highwire
Dec 20150133pmc
Jan 20163100Highwire
Jan 2016051pmc
Feb 20167500Highwire
Feb 2016064pmc
Mar 20162502Highwire
Mar 2016084pmc
Apr 20162702Highwire
Apr 2016076pmc
May 20161900Highwire
May 20160116pmc
Jun 20162400Highwire
Jun 2016064pmc
Jul 20163700Highwire
Jul 2016054pmc
Aug 20164801Highwire
Aug 2016010pmc
Sep 20163200Highwire
Sep 2016011pmc
Oct 20165500Highwire
Oct 20160101pmc
Nov 20163200Highwire
Nov 2016042pmc
Dec 20162500Highwire
Dec 20160184pmc
Jan 20173800Highwire
Jan 2017062pmc
Feb 20173000Highwire
Feb 2017031pmc
Mar 20172200Highwire
Mar 2017041pmc
Apr 20172500Highwire
Apr 2017033pmc
May 20171700Highwire
May 2017565pmc
Jun 20171400Highwire
Jun 2017155pmc
Jul 20171300Highwire
Jul 201731011pmc
Aug 20171900Highwire
Aug 2017022pmc
Sep 20171810Highwire
Sep 2017298pmc
Oct 20172610Highwire
Oct 2017498pmc
Nov 20172200Highwire
Nov 2017066pmc
Dec 20172800Highwire
Jan 20182800Highwire
Feb 20183500Highwire
Mar 20183301Highwire
Apr 20183900Highwire
Apr 2018155pmc
May 20182221Highwire
Jun 20183400Highwire
Jun 2018156pmc
Jul 20182321Highwire
Aug 20182600Highwire
Aug 2018056pmc
Sep 20181411Highwire
Oct 20182011Highwire
Nov 20182400Highwire
Dec 20182500Highwire
Jan 20192100Highwire
Feb 20191500Highwire
Mar 20191400Highwire
Apr 20191710Highwire
May 20191200Highwire
Jun 20191110Highwire
Jul 20192000Highwire
Aug 2019901Highwire
Sep 2019600Highwire
Oct 20191210Highwire
Nov 20192200Highwire
Dec 2019901Highwire
Jan 20202100Highwire
Feb 20201210Highwire
Mar 20201400Highwire
Apr 2020310Highwire
May 2020400Highwire
Jun 20201500Highwire
Jul 20201200Highwire
Aug 20202200Highwire
Sep 20201900Highwire
Oct 2020500Highwire
Nov 20201110Highwire
Dec 20201820Highwire
Jan 20211600Highwire
Feb 20211200Highwire
Mar 20211810Highwire
Apr 20212310Highwire
May 20211311Highwire
Jun 20211510Highwire
Jul 20212011Highwire
Aug 20212220Highwire
Sep 20212200Highwire
Oct 20211900Highwire
Nov 20212011Highwire
Dec 20211910Highwire
Jan 20221613Highwire
Feb 20222500Highwire
Mar 20224300Highwire
Apr 20222500Highwire
May 20222400Highwire
Jun 20222611Highwire
Jul 20221501Highwire
Aug 20222800Highwire
Sep 20221200Highwire
Oct 20222211Highwire
Nov 20222322Highwire
Dec 20224700Highwire
Jan 20232710Highwire
Feb 20232700Highwire
Mar 20232200Highwire
Apr 20231300Highwire
May 20231211Highwire
Jun 20231023Highwire
Jul 20231300Highwire
Aug 20232000Highwire
Sep 202310911Highwire
Oct 20232600Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles